ArticleClinical ophthalmology (Auckland, N.Z.)2026
Clinical and Patient-Reported Outcomes of Premium Intraocular Lenses in Glaucoma Patients Undergoing Combined Cataract and Minimally Invasive Glaucoma Surgery.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Premium intraocular lenses (IOLs), including multifocal, extended depth-of-focus (EDOF), and light adjustable lenses (LALs) are used to reduce spectacle dependence after cataract surgery. However, their use in glaucoma patients remains controversial due to concerns that reduced contrast sensitivity and pre-existing visual field loss limits functional benefits from these optics. Increasing use of minimally invasive glaucoma surgery (MIGS) at the time of cataract surgery has made combined refractive and glaucoma management more common, but data on real world outcomes remains limited. Methods: This single-center, IRB-approved retrospective observational study with cross-sectional survey analysis included glaucoma patients who underwent bilateral cataract surgery with implantation of multifocal, EDOF, or LAL IOLs with concurrent MIGS from 2020 to 2025. Postoperative visual outcomes, intraocular pressure (IOP), glaucoma medication burden, spectacle dependence, dysphotopsias, and patient satisfaction were assessed. Longitudinal outcomes were analyzed using mixed-effects models adjusted for baseline glaucoma severity (mean deviation). Satisfaction was evaluated using proportional odds logistic regression adjusting for age and baseline disease severity. Results: Seventy-nine patients (Multifocal n=43, EDOF n=24, LAL n=12) were included. All groups demonstrated significant postoperative improvement in distance visual acuity and reduction in IOP and glaucoma medication burden. Adjusted IOP trajectories and most recent IOP were similar between groups. Distance visual acuity outcomes were similar between groups after adjustment for baseline glaucoma severity. Near visual acuity favored multifocal IOLs, while LAL demonstrated the highest spectacle dependence. Dysphotopsias were more frequent with multifocal lenses and lowest in LAL. Satisfaction was high across all groups, with predicted probabilities of being "very" or "somewhat satisfied" of 94% (multifocal), 88% (EDOF), and 87% (LAL). Conclusions: In appropriately selected glaucoma patients undergoing cataract surgery with MIGS, multifocal, EDOF, and LAL IOLs provide comparable visual outcomes, excellent IOP control, and high satisfaction. Differences in spectacle dependence and dysphotopsia support individualized IOL selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.